English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

Mutations in the gene encoding the main cardiac sodium channel (SCN5A) are the commonest genetic cause of Brugada syndrome (BrS). However, the effect of SCN5A mutations on the outcomes of ventricular fibrillation ( VF ) and syncope remains uncertain. To clarify this relationship, a meta‐analysis was performed. A comprehensive search was conducted to identify all eligible studies from PubMed,  MEDLINE ,  EBSCO , ProQuest, Science Direct, Clinical Key, and Cochrane database for cohort studies of BrS populations that had been systematically tested for  SCN 5A mutations. We did meta‐analysis to see the relationship between  SCN 5A mutations and the occurrence of  VF  and/or syncope using RevMan 5.3. Five clinical studies met our criteria and included a total of 665 BrS patients. These studies included 45 patients with  VF  and 178 patients with syncope. We found that in BrS patients with  SCN 5A mutations the rate of  VF  event was 30.7% while in patients without mutations was 28.5% (Risk Ratio [ RR ] = 1.11, [95%  CI : 0.61, 2.00],  P  = 0.73,  I  2  = 0%). The occurrence of syncope events was 35.9% in patients with  SCN 5A mutations and 34.5% in patients without mutations ( RR  = 1.12, [95%  CI : 0.87, 1.45],  P  = 0.37,  I  2  = 39%). Furthermore, the occurrence of combined  VF  and syncope events were similar between the 2 groups ( RR  = 1.12, [95%  CI : 0.89, 1.42],  P  = 0.34,  I  2  = 11%). BrS patients with  SCN 5A mutations exhibit a similar risk of future occurence of  VF  and/or syncope as compared to those without  SCN 5A mutations.

SCN 5A gene mutations and the risk of ventricular fibrillation and syncope in Brugada syndrome patients: A meta‐analysis